Joaquín Gómez Gómez, Ana Polanco, Joaquín Gómez Moya and Javier Lucas at the Biotechnology Day – La Opinión
The biotechnology sector in the Region of Murcia is one of the fastest growing in Spain. The Bioindustry Association of the Region of Murcia (Abiomur) has been created to transfer the values of its activities and its health, agrifood and environmental benefits, to our society.
Joaquín Gómez Moya, CEO of Viva In Vitro Diagnostics and partner and advisor at BHV Partners, has been appointed chairman of the new business association. The positions of vice-chair of Health and Agrifood went to Rafael Valverde, CEO of Inbentus and Javier Lucas, general manager of AgroLucas, respectively. Toni Vilaplana was named general secretary.
Abiomur officially launched on 23 June in front of 100 sector professionals at the second Biotechnology Day Trends in Spain and the Region of Murcia, organised by the newspaper La Opinión and the Instituto de Fomento de la Región de Murcia.
The day included presentations from experts and institutional representatives such as Joaquín Gómez Gómez, director of the Instituto de Fomento de la Región de Murcia; Ana Polanco, chairwoman of the Spanish Bioindustry Association (AseBio); Joaquín Gómez Moya, chairman of Abiomur; Javier Lucas, vice-chairman of Abiomur and Pere Condom, director of the University of Girona (UdG) Office of Research and Technology Transfer and partner and advisor at BHV Partners. They were welcomed by the editor-in-chief of La Opinión, Lola García.
“We predict a dawning of the business ecosystem in the biohealth sector”, highlighted Joaquín Gómez Gómez.
“The Region of Murcia is setting itself up as an incubator for science and technology start-ups whose contribution to medical and hospital treatment will become a considerable force in the region’s GDP as the projects continue to mature”, explained Joaquín Gómez Moya.
Abiomur’s activity is already under way and represents the interests of its members and cooperates in organising activities and platforms to attract investment, talent and partnerships to the industry. Abiomur already has 22 members and is open to companies, research institutions, venture builders, accelerators, and venture capital. Gómez Moya describes this in detail in his article Abiomur: capital, impacto y talento biotecnológico, written for La Opinión.
If you were unable to attend the day, you can catch it on the following link: